Physician profile
Kyle B Basham
NPI 1043573355
$30,473.52
in general payments reported to CMS, 2019-2025
37 companies · $2,006 in 2025
The $2,006 reported for 2025 was more than what 80% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,079 · 2020: $139 · 2021: $16K · 2022: $6,934 · 2023: $2,279 · 2024: $1,372 · 2025: $2,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,656.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $18,593.72 | 2021-2025 | |
| Axonics, INC. | $2,344.02 | 2020-2024 | Axonics, Bulkamid |
| Neotract INC. | $1,341.75 | 2019 | |
| Procept Biorobotics Corporation | $1,238.65 | 2021-2025 | Aquabeam Robotic System, Aquabeam System |
| Medtronic, INC. | $1,163.17 | 2021-2025 | Interstim, Altaviva |
| Boston Scientific Corporation | $1,120.52 | 2019-2025 | Advantage System, Solyx Sis System, Upsylon |
| Coloplast Corp | $1,046.47 | 2019-2025 | Titan |
| Bayer Healthcare Pharmaceuticals INC. | $475.65 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $300.81 | 2023-2025 | Orgovyx, Gemtesa |
| Endo Pharmaceuticals INC. | $267.05 | 2019-2024 | Xiaflex, Aveed |
| Astellas Pharma US INC | $261.96 | 2019-2024 | Xtandi |
| Ethicon US, LLC | $260.50 | 2019-2023 | Stratafix |
| Janssen Biotech, INC. | $240.51 | 2019-2025 | Erleada, Akeega |
| Myriad Genetic Laboratories, INC. | $231.21 | 2021-2025 | Prolaris |
| Myovant Sciences INC. | $216.95 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $172.68 | 2021-2022 | |
| Pfizer INC. | $172.63 | 2019-2025 | |
| Abbvie INC. | $114.98 | 2022-2025 | Botox |
| Allergan, INC. | $104.06 | 2019-2022 | |
| Laborie Medical Technologies Corp. | $96.85 | 2023 | |
| Blue Earth Diagnostics | $90.24 | 2021-2022 | |
| Teleflex LLC | $76.98 | 2024-2025 | Urolift, Barrigel |
| Dendreon Pharmaceuticals LLC | $76.11 | 2019-2025 | Provenge |
| Ambu INC. | $74.93 | 2025 | |
| Olympus America INC. | $62.13 | 2023 | Itind System |
| Progenics Pharmaceuticals, INC. | $59.18 | 2025 | |
| Antares Pharma, INC. | $44.49 | 2021-2025 | Xyosted |
| Cook Medical LLC | $39.45 | 2019-2023 | Fiber Dust |
| Astrazeneca Pharmaceuticals LP | $34.13 | 2021 | |
| Urovant Sciences INC | $32.62 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $22.31 | 2023 | Bard Urinary Drainage Bag |
| Kowa Pharmaceuticals America, INC. | $19.65 | 2023 | Seglentis |
| Accord Healthcare, INC. | $17.69 | 2023 | |
| Photocure INC | $17.68 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $15.14 | 2021 | |
| Medtronic USA, INC. | $13.33 | 2019 | |
| Merck Sharp & Dohme LLC | $13.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Basham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.